respiratory
Asthma Symptom Control (GINA)
GINA (Global Initiative for Asthma) 2023 severity and control classification. Guides step-up/step-down of inhaled therapy from Step 1 (PRN SABA) to Step 5 (biologic therapy).
Used in: Asthma
Score interpretation
Well Controlled 0
None of the four GINA control items.
→ Continue; review at regular intervals.
Partly Controlled 1–2
1–2 of the four GINA control items.
→ Review inhaler technique, adherence and treatment step.
Uncontrolled 3–4
3–4 of the four GINA control items.
→ Review and step up treatment per GINA / BTS-NICE-SIGN.
Interpretation bands for the GINA Asthma Severity. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Fluticasone Furoate / Vilanterol · ICS/LABA — Asthma / COPD
- Beclometasone / Formoterol · ICS/LABA — Asthma / COPD
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Tezepelumab (CRSwNP / Severe Asthma) · Anti-TSLP (Thymic Stromal Lymphopoietin) Monoclonal Antibody
- Morphine (Oral) · Strong Opioid Analgesic — Step 3 WHO Ladder
- Oxycodone · Strong Opioid Analgesic — Step 3 WHO Ladder
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
